We are live on ! Find out more
AZN icon

AstraZeneca

1,224 hedge funds and large institutions have $34.7B invested in AstraZeneca in 2025 Q2 according to their latest regulatory filings, with 82 funds opening new positions, 461 increasing their positions, 441 reducing their positions, and 113 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more call options, than puts

Call options by funds: $596M | Put options by funds: $259M

5% more repeat investments, than reductions

Existing positions increased: 461 | Existing positions reduced: 441

0.3% less ownership

Funds ownership: 16.3% → 16% (-0.3%)

2% less funds holding

Funds holding: 1,252 → 1,224 (-28)

26% less capital inflows, than outflows

Capital inflows: $1.95B | Capital outflows: $2.64B

27% less first-time investments, than exits

New positions opened: 82 | Existing positions closed: 113

50% less funds holding in top 10

Funds holding in top 10: 22 → 11 (-11)

Holders
1,224
Holders Change
-28
Holders Change %
-2.24%
% of All Funds
16.04%
Holding in Top 10
11
Holding in Top 10 Change
-11
Holding in Top 10 Change %
-50%
% of All Funds
0.14%
New
82
Increased
461
Reduced
441
Closed
113
Calls
$596​M
Puts
$259​M
Net Calls
+$337​M
Net Calls Change
-⁠$224​M

AZN Hedge Fund Activity: Q2 2025 in Review

1,224 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2025, worth a combined $34.7B — down 7% from $37.3B a quarter earlier.

Sellers outnumbered buyers: 113 funds closed out of AZN and 82 opened new positions — a net loss of 31 holders — while 441 trimmed existing stakes and 461 added.

The largest buyer was Fayez Sarofim & Co, adding an estimated $166M. The largest seller was T. Rowe Price Associates, cutting an estimated $360M.

  • 1,224 institutional investors held AstraZeneca (AZN) as of Q2 2025, down from 1,252 in Q1 2025.
  • Funds reported $34.7B of AstraZeneca stock for Q2 2025, down 7% quarter-over-quarter.
  • 82 funds opened new AstraZeneca positions in Q2 2025 and 113 closed out, a net change of -31 holders.
  • The largest AstraZeneca buyer in Q2 2025 was Fayez Sarofim & Co, an estimated $166M added.
  • The largest AstraZeneca seller in Q2 2025 was T. Rowe Price Associates, an estimated $360M sold.

Based on aggregated 13F filings for Q2 2025.